Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new risk model, developed by UK researchers to predict a person’s risk of being admitted to hospital and dying from Covid-19 has been published by The BMJ

Family members seeing each other through window pane © Shutterstock

A model that can calculate a person’s risk of becoming infected and then seriously ill due to COVID-19 has been shown to accurately estimate risk during the first wave of the pandemic in England, in new research led by a team from the University of Oxford.

The model, developed using routine anonymised data from more than 8 million adults in 1205 general practices across England, uses a number of factors such as a person’s age, ethnicity and existing medical conditions to predict their risk of catching COVID-19 and then dying or being admitted to hospital.

The model has the potential to provide doctors and the public with more nuanced information about risk of serious illness due to COVID-19, and to help patients and doctors reach a shared understanding of risk, within the context of individual circumstances, risk appetite and the sorts of preventative measures people can take in their daily lives.

The full story is available on the Nuffield Department of Primary Care Health Sciences website

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.